Italia - italiano - myHealthbox

guna - roe extract, acido jaluronico, inositolo, estratto di luppolo, estratto di cacao, ginseng, guaranÀ,estratto di loto, dna e rna idrolizzanti, estratto di maca - siero - aqua/water, dimethicone, decyl oleate, glycerin, butylene glycol, dipropylene glycol, bis-peg/ppg-16/16 peg/ppg-16/16 dimethicone, saccharomyces/copper ferment, saccharomyces ferment, saccharomyces/magnesium ferment, saccharomyces/silicon ferment, saccharo - cosmetici - creme

Italia - italiano - myHealthbox

guna - roe extract, gingko biloba, salvia officinalis, vitamina e - lozione - aqua/water, alcohol denat., butylene glycol, glycerin, salvia officinalis extract, ginkgo biloba extract, cinnamomunm zeylanicum extract, ppg-26-buteth-26, peg-40 hydrogenated castor oil, apigenin, oleanolic acid, biotinoyl tripeptide-1, roe extract, ethyl - cosmetici - creme

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

aeffe farmaceutici srl - idrocortisone - idrocortisone

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

dynacren laboratorio farmaceutico del dott.a.francioni e di m.gerosa s.r.l. - idrocortisone - idrocortisone

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

dynacren laboratorio farmaceutico del dott.a.francioni e di m.gerosa s.r.l. - idrocortisone - idrocortisone

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

dompe' farmaceutici s.p.a. - idrocortisone - idrocortisone

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

leo pharma a/s - idrocortisone e antibiotici - idrocortisone e antibiotici

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - haemagglutininum influenzae a (h1n1) (virus stamm a/victoria/2570/2019 (h1n1)-like: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus stamm a/cambodia/e0826360/2020 (h3n2)-like: reassortant virus ivr-221 derived from a/tasmania/503/2020), haemagglutininum influenzae b (virus stamm b/washington/02/2019-like: reassortant virus b/washington/02/2019 (victoria lineage)) - sospensione iniettabile - haemagglutininum influenzae a (h1n1) (virus stamm a/victoria/2570/2019 (h1n1)-like: reassortant virus ivr-215 derived from a/victoria/2570/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus stamm a/cambodia/e0826360/2020 (h3n2)-like: reassortant virus ivr-221 derived from a/tasmania/503/2020) 15 µg, haemagglutininum influenzae b (virus stamm b/washington/02/2019-like: reassortant virus b/washington/02/2019 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus stamm b/phuket/3073/2013 (yamagata lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alpha-tocopheroli hydrogenosuccinas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml, residui: ovalbuminum, formaldehydum, natrii desoxycholas, gentamicini sulfas, hydrocortisonum. - immunizzazione attiva contro l'influenza, a partire da 36 mesi - vaccini

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - haemagglutininum influenzae a (h1n1) (virus stamm a/victoria/2570/2019 (h1n1)pdm09-like: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus stamm a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-227 derived from a/darwin/6/2021), haemagglutininum influenzae b (virus stamm b/austria/1359417/2021-like: reassortant virus bvr-26 derived from b/austria/1359417/2021 (victoria lineage)) - sospensione iniettabile - haemagglutininum influenzae a (h1n1) (virus stamm a/victoria/2570/2019 (h1n1)pdm09-like: reassortant virus ivr-215 derived from a/victoria/2570/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus stamm a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-227 derived from a/darwin/6/2021) 15 µg, haemagglutininum influenzae b (virus stamm b/austria/1359417/2021-like: reassortant virus bvr-26 derived from b/austria/1359417/2021 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus stamm b/phuket/3073/2013-like: b/phuket/3073/2013 wild type (yamagata lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alpha-tocopheroli hydrogenosuccinas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml, residui: ovalbuminum, formaldehydum, natrii desoxycholas, gentamicini sulfas, hydrocortisonum. - immunizzazione attiva contro l'influenza, a partire da 36 mesi - vaccini

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - haemagglutininum influenzae a (h1n1) (virus stamm a/victoria/4897/2022 (h1n1)pdm09-like: reassortant virus ivr-238 derived from a/victoria/4897/2022), haemagglutininum influenzae a (h3n2) (virus stamm a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-227 derived from a/darwin/6/2021), haemagglutininum influenzae b (virus stamm b/austria/1359417/2021-like: reassortant virus bvr-26 derived from b/austria/1359417/2021 (victoria lineage)) - sospensione iniettabile - haemagglutininum influenzae a (h1n1) (virus stamm a/victoria/4897/2022 (h1n1)pdm09-like: reassortant virus ivr-238 derived from a/victoria/4897/2022) 15 µg, haemagglutininum influenzae a (h3n2) (virus stamm a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-227 derived from a/darwin/6/2021) 15 µg, haemagglutininum influenzae b (virus stamm b/austria/1359417/2021-like: reassortant virus bvr-26 derived from b/austria/1359417/2021 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus stamm b/phuket/3073/2013-like: b/phuket/3073/2013 wild type (yamagata lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alpha-tocopheroli hydrogenosuccinas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml, residui: ovalbuminum, formaldehydum, natrii desoxycholas, gentamicini sulfas, hydrocortisonum. - immunizzazione attiva contro l'influenza, a partire da 36 mesi - vaccini